

# THE MAIN HUBS OF ERN-EUROBLOODNET COORDINATION

**Assistance Publique - Hôpitaux de Paris (AP-HP)**  
Prof. Pierre Fenaux, ERN Coordinator, Chair of the oncological hub  
([pierre.fenaux@aphp.fr](mailto:pierre.fenaux@aphp.fr))

**Université libre de Bruxelles (ULB/Hôp. Erasme HUB)**  
Prof. Béatrice Gulbis, ERN co-Coordinator, Chair of the non-oncological hub  
([beatrice.gulbis@lhub-ulg.be](mailto:beatrice.gulbis@lhub-ulg.be))

**Vall d'Hebron University Hospital - Vall d'Hebron Research Institute (HUVH/VHIR)**  
Dr María del Mar Mañú-Pereira, ERN Scientific director and Coordinator of ENROL registry  
([mar.manu@vhir.org](mailto:mar.manu@vhir.org))

If you are a patient, a patient care giver or a professional dealing with rare hematological diseases, contact us,  
**ERN-EuroBloodNet is working to assist your needs!**



Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.

© ERN-EuroBloodNet, May 2024



**ebon**  
ERN | EuroBloodNet

## The European Reference Network on Rare Hematological Diseases

Individuals and institutions committed to improving  
healthcare services in rare hematological diseases



ERN-EuroBloodNet is a collaborative network aiming to **improve the healthcare services of complex or rare hematological diseases (RHD) and conditions that require highly specialized treatment in Europe.**  
 ERN-EuroBloodNet disease coverage involves **more than 450 RHDs according to ORPHA classification** encompassing oncological (for adult patients) and non-oncological diseases (for adult and pediatric patients).

## THE DISEASE COVERAGE DIVIDED INTO 6 MEDICAL AREAS, SO CALLED SUBNETWORKS

### ONCOLOGICAL HUB

- Myeloid malignancies
- Lymphoid malignancies

### NON-ONCOLOGICAL HUB

- Rare red blood cell defects
- Bone marrow failure and hematopoietic disorders
- Rare bleeding-coagulation disorders and related diseases
- Hemochromatosis and other rare genetic disorders of iron metabolism and heme synthesis

Methodological approach of ERN-EuroBloodNet shaped in accordance with ongoing EU activities, contributing to innovative, efficient and sustainable health systems and facilitating the access to a better and safer healthcare for EU citizens. **In accordance with the Directive on Cross-Border Healthcare (2011/24/EU), our efforts are undertaken to improve the delivery of cross-border care to RHD patients.**

## WE HAVE DEFINED FIVE TRANSVERSAL FIELD OF ACTIONS (TFAs)



**Cross Border Health:** Enhancing equal access to highly specialized outcome-based healthcare and cross-border health for RHD in EU.



**Telemedicine:** Enabling the safe exchange of clinical information between healthcare professionals in order to provide expert advice about complex RHD cases through the Clinical Patient Management System (CPMS).



**Best Practices:** Promoting best practice in prevention, diagnosis and clinical care across EU by the development and update of ERN Clinical Practice Guidelines and other Clinical Decision Making tools.



**Clinical trials & research:** Strengthening the use and re-use of RHD health data through the European Rare Blood Disorders Platform (ENROL) for the provision of best healthcare and for the promotion of research and innovation.



**Continuing Medical Education:** Spreading cutting-edge knowledge and facilitate continuing medical education in the field of RHDs.

## THE ERN-EUROBLOODNET THREE MAIN GOVERNING BODIES

### ERN COORDINATION

Ensures the proper operational management of the network and the smooth functioning among the key players. Three main medical-scientific coordination centers make up the coordination team and ensure the deployment of the ERN strategic plan and the achievement of its objectives: Assistance Publique - Hôpitaux de Paris (AP-HP, ERN-EuroBloodNet coordinator), Université libre de Bruxelles (ULB/Hôp. Erasme HUB) and Vall d'Hebron University Hospital - Vall d'Hebron Research Institute (HUVH/VHIR).


### BOARD OF THE NETWORK (BoN)

The decision-making body, composed by all Members and Affiliated Partners representatives, and the ERN European Patients Advocacy Groups (ePAGs).

### SCIENTIFIC AND STRATEGIC BOARD

Develops the multi-annual work plan, oversees ERN-EuroBloodNet actions, and assesses their impact. Composed by ERN Coordination, TFAs Coordinators, Subnetworks Coordinators and leaders of ongoing actions.

The BoN comprises **97 HCPs from 24 EU Member States and 11 ePAGs Affiliated to 11 different International or European Patients Networks and EURORDIS.** This work team ensures the involvement of both clinical and patients voices.



The ERN-EuroBloodNet Stakeholders Group (SG) assists the three governing bodies. SG includes:

- Supporting Partners (clinical or research)
- European Hematology Association (EHA)
- Other ERNs and Networks consortiums
- Orphanet
- EURORDIS